Thermo Fisher Scientific CD27 Monoclonal Antibody (O323), Brilliant Ultra Violet 395, eBioscience

Thermo Fisher Scientific CD27 Monoclonal Antibody (O323), Brilliant Ultra Violet 395, eBioscience™

Applications and Tested Dilution

• Application: Flow Cytometry (Flow)
• Tested Dilution: 5 µL (0.5 µg)/test

Product Specifications

Available Formats

• Unconjugated
• Alexa Fluor 700
• APC
• APC-eFluor 780
• Biotin
• Brilliant UV 563 / 615 / 737 / 805
• Brilliant Violet 421 / 480 / 605 / 711
• eFluor 450
• FITC
• NovaFluor Blue / Red / UV / Violet / Yellow series
• PE / PE-Cyanine5 / PE-Cyanine7 / PE-eFluor 610
• PerCP-eFluor 710
• Super Bright 436 / 600 / 645 / 702 / 780
• Custom conjugation available

Product Specific Information

Description:
The O323 monoclonal antibody reacts with human CD27, a lymphocyte-specific member of the TNFR superfamily. CD27 is expressed by thymocytes and mature T cells and is upregulated upon T-cell stimulation. It binds to CD70, playing a critical role in T cell–B cell interaction.

Applications Reported:
Suitable for flow cytometric analysis.

Applications Tested:
Pre-diluted and validated for flow cytometric analysis of normal human peripheral blood cells. Recommended use: 5 µL (0.5 µg) per test (100 µL final volume, 10⁵–10⁸ cells/test).

Fluorochrome Information:
Brilliant Ultra Violet™ 395 (BUV395) emits at 395 nm and is optimized for ultraviolet (355 nm) laser-equipped cytometers. Ensure instrument compatibility before use.

Buffer Recommendation:
For panels using multiple polymer dye-conjugated antibodies, use Super Bright Complete Staining Buffer (SB-4401-42) or Brilliant Stain Buffer™ (00-4409-75) to minimize non-specific interactions.

Spectral Properties:

• Excitation: 350 nm
• Emission: 395 nm
• Laser: Ultraviolet

Trademark Notice:
BRILLIANT ULTRA VIOLET™ is a trademark of Becton, Dickinson and Company. Powered by Sirigen™.

Target Information

CD27 is a 50 kDa member of the TNF receptor superfamily, expressed mainly on lymphocytes. It forms a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells, and some B cells. Activation via TCR-CD3 increases CD27 expression and release of soluble CD27 (sCD27), a prognostic marker for B cell malignancies. CD27 interacts with CD70 and SIVA, influencing T cell activation and apoptosis. Dysregulation is associated with Lymphoproliferative Syndromes.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without authorization.

제품 이미지